Hong Kong-based GenEditBio, a biotech company specializing in precision genome editing, has secured a strategic investment from Gobi Partners GBA. This investment aims to accelerate the development of GenEditBio's genome editing and delivery technologies, advance its in vivo programs, and initiate clinical studies to assess the safety and efficacy of its therapies.
Advancing In Vivo Programs
GenEditBio's in vivo programs, GEB-100 and GEB-200, utilize proprietary lipid nanoparticles (LNPs) to target the liver. These programs have completed proof-of-concept studies in non-human primates and are on track to nominate drug candidates in the third quarter of 2024. The GEB-400 program, which targets an inherited retinal disease, is expected to nominate a drug candidate in 2024 and enter the clinical stage in 2025. This program will showcase the company's next-generation delivery technology, known as ePDVs (engineered protein delivery vehicles).
Leadership Perspectives
"We are excited to partner with Gobi Partners GBA and leverage on their rich experience in nurturing start-ups into successful businesses," said ZHENG Zongli, PhD, Co-Founder and Chairman of GenEditBio. "This investment will allow us to cultivate our talent pool, accelerate our research engine and transform our cutting-edge genome-editing and drug delivery technologies to life-changing therapeutics to those in desperate need."
ZHU Tian, PhD, Co-Founder and CEO of GenEditBio, added, "This investment will enable us to stay at the forefront of genome editing as well as novel delivery and advance our multiple pipeline programs towards clinical studies. We are grateful for such strong support. Their extensive network of public and private sector partners and expertise in the biotech industry will be invaluable to realise our ambitious goals as we continue to innovate and excel."
About GenEditBio
Founded in 2021, GenEditBio is dedicated to providing potentially curative, once-and-done, and programmable in vivo genome editing-based therapeutic solutions, dubbed "DNA surgery," for genetic diseases lacking effective treatments. The company focuses on novel Cas nuclease discovery and safe and efficient cargo delivery using LNPs and ePDVs. GenEditBio has research laboratories and supporting offices in Hong Kong, Beijing, and Boston.
